18 results
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
to, or errors in, critical business and financial information, substantial capital expenditures, additional administrative time and operating expenses, retention
8-K
EX-10.1
MIRA
Mira Pharmaceuticals Inc
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
with appropriate representatives of Licensee.
2.10 Records Retention and Audits. Licensee agrees to keep true and accurate records, files, and books
424B4
MIRA
Mira Pharmaceuticals Inc
4 Aug 23
Prospectus supplement with pricing info
1:01pm
capital expenditures, additional administrative time and operating expenses, retention of sufficiently skilled personnel to implement and operate
424B1
MIRA
Mira Pharmaceuticals Inc
4 Aug 23
Prospectus with pricing info
12:59pm
, additional administrative time and operating expenses, retention of sufficiently skilled personnel to implement and operate the enhanced systems
S-1
EX-99.3
rsh5o3 7t
29 Jun 23
IPO registration
4:39pm
S-1
EX-10.4
29ih2d90vias
29 Jun 23
IPO registration
4:39pm
S-1
EX-99.1
2n6e7j3botql30mh10
29 Jun 23
IPO registration
4:39pm
S-1
9ut3i6 r6thpkc5hx
29 Jun 23
IPO registration
4:39pm
DRS/A
EX-10.4
71g9ke jiezc8u
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
EX-99.3
wldvol1 459tvsv
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
7g54z zuna
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
EX-99.1
o6r050
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
y0hhnf
2 May 23
Draft registration statement (amended)
12:00am
DRS
9e8fbo1 lhe5zoh1vo8
29 Jun 22
Draft registration statement
12:00am
- Prev
- 1
- Next